Edogawa Hospital, which provides BNCT (Boron Neutron Capture Therapy) as a self-pay medical service, reports progress on Phase 2 (efficacy confirmation) of its specific clinical research on BNCT.

Frequently Asked Questions

Q: What is BNCT (Boron Neutron Capture Therapy) as provided by Edogawa Hospital?

A: BNCT is a radiation therapy that uses boron compounds taken up by cancer cells to trigger a reaction within tumor cells through neutron irradiation.

Q: What is the purpose of Edogawa Hospital's specific clinical research on BNCT?

A: The specific clinical research aims to evaluate treatments at medical institutions and is currently in Phase 2, focusing on efficacy confirmation and expanding target diseases.

Q: What positive treatment progress has been observed in Edogawa Hospital's Phase 2 BNCT research?

A: Favorable treatment progress, including tumor disappearance (Complete Response: CR), has been confirmed in cases of recurrent and untreated primary breast cancer.

Q: What is the latest report on Edogawa Hospital's specific clinical research for BNCT?

A: The latest report details Phase 2 research targeting FDG-PET positive superficial tumors, which began in August 2024 and enrolled 10 patients.

Q: How does the new BNCT research at Edogawa Hospital utilize FDG-PET instead of FBPA-PET?

A: This study uses FDG-PET to evaluate and examine its utility for assessing boron compound accumulation, as FDG-PET is more widely available in clinical practice compared to FBPA-PET.